Carboxylesterases of human brain extract Purification and properties of a butyrylesterase

1977 ◽  
Vol 481 (2) ◽  
pp. 500-514 ◽  
Author(s):  
Nina Højring ◽  
Ole Svensmark
1985 ◽  
Vol 45 (6) ◽  
pp. 1903-1910 ◽  
Author(s):  
Jacques-Andre Maring ◽  
Richard A. Deitrich ◽  
Roger Little

2019 ◽  
Vol 21 (Supplement_4) ◽  
pp. iv7-iv7
Author(s):  
Mohammed Diksin ◽  
Jonathan Rowlinson ◽  
Alexandar Kondrashov ◽  
Chris Denning ◽  
Jamie Hughes ◽  
...  

Abstract Glioblastoma therapeutic challenges are in considerable part due to myriad survival adaptations and mechanisms, which allow malignant cells to repurpose signalling pathways within discreet microenvironments. These Darwinian adaptations facilitate invasion into brain parenchyma and perivascular space or promote evasion from repressive factors that represent anti-cancer defence mechanisms. We hypothesised that pre-clinical modelling of glioma invasion by recapitulating early events occurring immediately after surgery at the glioblastoma invasive margin, could reveal the cross-talk between malignant cells and the surrounding healthy astrocytes, which facilitates tumour recurrence. We first generated transgenic H1-derived neural stem cells using CRISPR/Cas9-mediated knock-in of the YFP reporter gene under the control of the GFAP promoter. Reproducible ultrahigh-throughput AggreWells™ (19,200 micro-wells per 24-well plate) were used to create astrocyte-glioblastoma organoids, which we term ‘Gliomasphere Matrices’. YFP-labelled astrocytes were co-cultured with 10 treatment-naïve patient-derived cell lines isolated from the 5-aminolevulinic (5ALA)-determined glioblastoma invasive margin. Co-cultures were seeded upon on a sequentially constructed, time-of-flight secondary ion mass spectrometry (ToF-SIMS)-characterised 3D scaffold, composed of decellularised human brain extract with defined PEGDA hydrogel. YFP-astrocytes were purified from each of the 10 Gliomasphere Matrices using fluorescence-activated cell sorting (FACS) after 6- and 10-days co-culture. RNAseq profiling to address both putative astrocytic reprogramming by invasive glioblastoma cells and gene expression changes intrinsic to tumour cells will be discussed in relation to RNAseq data from patient-derived 5ALA FACS-purified glioblastoma invasive margin tissue. This novel multi-faceted model offers a unique opportunity to recapitulate early molecular cross-talk which facilitates glioblastoma recurrence and may be utilised for high-throughput drug screening.


2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi264-vi265
Author(s):  
Mohammed Diksin ◽  
Jonathan Rowlinson ◽  
Alexander Kondrashov ◽  
Chris Denning ◽  
Jaime Hughes ◽  
...  

Abstract Glioblastoma therapeutic challenges are in considerable part due to myriad survival mechanisms which allow malignant cells to repurpose signalling pathways within discreet microenvironments. These Darwinian adaptations facilitate invasion into brain parenchyma and perivascular space. We hypothesised that pre-clinical modelling of glioma invasion by recapitulating early events occurring immediately after surgery at the glioblastoma invasive margin, could reveal the cross-talk between malignant cells and surrounding healthy astrocytes. We first generated transgenic H1-derived neural stem cells using CRISPR/Cas9-mediated knock-in of the YFP reporter gene under the control of the GFAP promoter at the AAVS1 safe harbour locus. Reproducible ultrahigh-throughput AggreWells™ (7200 mini-wells per plate) were used to create astrocyte-glioblastoma organoids, which we term ‘Gliomasphere Matrices’. YFP-labelled astrocytes were co-cultured with 10 treatment-naïve patient-derived cell lines isolated from the 5-aminolevulinic (5ALA)-determined glioblastoma invasive margin. Co-cultures were seeded upon a sequentially constructed, time-of-flight secondary ion mass spectrometry (ToF-SIMS)-characterised decellularised human brain extract. YFP-astrocytes were purified from each of the 10 Gliomasphere Matrices using fluorescence-activated cell sorting (FACS) after 6- and 10-days co-culture. RNA-sequencing of the putatively reprogrammed YFP-astrocytes showed the characteristic expression of canonical key regulators of multiple malignant diseases including high-grade glioma such as SND1 and EFNB2 in addition to the identification of a single novel marker located at chromosome 1 (C1orf61), highly expressed in malignant glioma when compared to somatic cancers according to TCGA RNA-sequencing data. Differentiated YFP-astrocytes also overexpressed IFITM2 and IFITM10, known to be involved in priming resistance against pathogenic microorganisms. This ultimately suggests a fluctuating state between malignant transformation imposed by the highly infiltrative glioma cells and the counter-action of the normal astrocytes to these deleterious invasive cells. This multi-faceted model offers a unique opportunity to recapitulate early molecular cross-talk which facilitates glioblastoma recurrence and may be utilised for high-throughput drug screening.


Biochemistry ◽  
1975 ◽  
Vol 14 (23) ◽  
pp. 5105-5110 ◽  
Author(s):  
Robert Roskoski ◽  
Chin-Tiong Lim ◽  
Laura M. Roskoski

1962 ◽  
Vol 08 (02) ◽  
pp. 286-296
Author(s):  
P Fantl ◽  
E. C Osborn

Summary1. A mixture of human serum or plasma and bovine plasma free of factors VII and X gave, with human brain extract, identical clotting times.2. An assay of factor VII in materials low in prothrombin using human plasma euglobulin was devised.3. Factor VII isolated from human plasma or serum gave similar activity with human brain extract.4. From a preparation containing factors VII and X which was added to human brain extract in the average 31% factor VII and 25% factor X was recovered. This was not dependent on the activity of factors VII and X in the original preparation. This indicates that factors VII and X are in equilibrium with tissue thromboplastin.5. Factors VII and X are not species specific but a higher concentration of these factors is required for prothrombin conversion in a heterologous reaction mixture.6. Factor VII activity is identical in silicone-coated or uncoated glass surfaces.


1980 ◽  
Vol 187 (1) ◽  
pp. 21-30 ◽  
Author(s):  
M M O'Brien ◽  
P J Schofield

Aldose reductase and hexonate dehydrogenase were isolated from human brain and partially purified. The two enzymes exhibited distinctive substrate-specificity profiles with a variety of aldoses, and aliphatic and aromatic aldehydes. Aldose reductase exhibited a high affinity for DL-glyceraldehyde (Km of 62 microM) and a low affinity (Km of 90 mM) for glucose, the physiological substrate of the polyol pathway. Hexonate dehydrogenase exhibited a relatively low affinity for D-glucuronate (Km of 4.6 mM) and a very low affinity for glucose (Km of 390 mM). Both enzymes exhibited a high specificity for NADPH, and both were inhibited competitively by NADP+. Hexonate dehydrogenase was inhibited by iodoacetate, iodoacetamide, N-ethylmaleimide and p-chloromercuribenzoate. Preincubation with 2-mercaptoethanol resulted in activation. Both enzymes were inhibited by a number of barbiturates (barbital, phenobarbital and pentobarbital) and by the central-nervous-system drugs diphenylhydantoin and ethosuccinimide. The substrate specificity and pattern of inhibition suggest that the two enzymes isolated correspond to two of four previously reported aldehyde reductases isolated from human brain.


1963 ◽  
Vol 10 (3) ◽  
pp. 201-211 ◽  
Author(s):  
A. S. Balasubramanian ◽  
B. K. Bachhawat

Sign in / Sign up

Export Citation Format

Share Document